The Joe Rogan ExperienceJoe Rogan Experience #1175 - Chris Kresser & Dr. Joel Kahn
CHAPTERS
- 0:02 – 4:39
Meet the debaters: a preventive vegan cardiologist vs. a functional medicine clinician
Joe introduces Dr. Joel Kahn as the vegan/plant-based cardiology voice and Chris Kresser as a functional medicine practitioner with a personal history of chronic illness. Both outline their training, clinical focus, and why they care about diet as medicine.
- 4:39 – 8:40
No one-size-fits-all diet: quality, context, and “nutritionism”
The conversation quickly converges on a key premise: asking for the single optimal diet for everyone is the wrong question. Kresser critiques “nutritionism” and the tendency to reduce diets to macronutrient percentages rather than food quality and context.
- 8:40 – 11:51
What epidemiology is—and why it’s controversial in nutrition
Joe asks for a plain-language explanation of epidemiology. Kahn defends it as one pillar of evidence among others, while Kresser argues nutrition epidemiology often starts with flawed assumptions and yields weak, confounded associations.
- 11:51 – 30:02
Kresser’s three big epidemiology problems: bad dietary recall, healthy-user bias, and tiny risk signals
Kresser lays out a structured critique: questionnaires are unreliable, health-conscious behaviors cluster (confounding), and typical nutrition relative risks are often too small to distinguish from chance. This frames later disputes about meat, cancer, and fat guidelines.
- 30:02 – 37:36
Processed meat and cancer: WHO/IARC claims vs. context and absolute risk
They debate what the WHO processed-meat classification means in practice. Kahn emphasizes population-level consequences even from small risk increases; Kresser stresses context (vegetables, cooking methods) and confounding in typical processed-meat eaters.
- 37:36 – 39:25
Practical ‘harm reduction’ tips: veggies with meat, marinades, and cooking chemistry
Kahn pivots to actionable advice: increasing vegetable intake can blunt some negative acute vascular effects of typical meals. They discuss how cooking methods and marinades can change formation of potentially harmful compounds.
- 39:25 – 44:52
The saturated fat showdown begins: why guidelines still say ‘limit it’
Joe pushes them into the central dispute: saturated fat and cholesterol guidance. Kahn argues global medical societies converge on limiting saturated fat based on biochemistry, metabolic ward studies, and population observations; Kresser argues newer meta-analyses don’t support the feared outcomes.
- 44:52 – 1:45:20
Meta-analyses vs. mechanistic biology: what counts as ‘best evidence’
They clash over evidence hierarchy. Kresser leans on meta-analyses of RCTs and large cohort reviews; Kahn argues meta-analyses can be manipulated and insists mechanisms and multiple evidence streams must align, citing Cochrane and Mendelian randomization work.
- 1:45:20 – 1:55:58
Guidelines, conflicts of interest, and whether institutions lag behind science
Joe repeatedly asks why major organizations keep recommending saturated fat limits if newer analyses disagree. Kresser argues institutions can be behind the curve and face industry conflicts; Kahn acknowledges funding problems but maintains consensus guidance reflects the best integrated evidence.
- 1:55:58 – 2:01:53
Individual variation and dietary context: saturated fat with sugar, eggs, and “nutrivore” framing
Kresser clarifies he’s not claiming saturated fat affects no one—some individuals are hyper-responders—but argues average outcomes don’t show the feared risks, especially in whole-food contexts. They explore why saturated fat plus refined carbs may be particularly problematic and briefly detour into eggs/cholesterol evidence.
- 2:01:53 – 2:12:14
Aging pathways and animal vs. plant protein: mTOR/IGF-1, mechanisms vs. outcomes
Kahn argues animal amino acid profiles (e.g., methionine/leucine) activate aging-related pathways (mTOR/IGF-1), tying this to observational findings on animal vs. plant protein and cancer risk. Kresser challenges mechanistic inference unless it consistently shows up in hard outcomes across robust evidence syntheses.
- 2:12:14 – 3:47:38
Back to LDL biology: receptors, statins, PCSK9, and emerging markers like TMAO
Kahn re-centers the cardiology model: LDL receptor biology, pharmacology (statins, PCSK9 inhibitors), and the clinical framing of lowering LDL early for lifelong benefit. He then tees up newer biomarkers (TMAO) as the discussion approaches the frontier of cardiometabolic risk research.
